PH
PHIO.US Phio Pharmaceuticals Corp
- Market cap
- USD 8.99M
- P/E
- -
- P/B
- 1.07x
- ROE
- -190.3%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is PHIO.US undervalued?
Graham numberThe Graham number of Phio Pharmaceuticals Corp cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Phio Pharmaceuticals Corp fundamental analysis
No fundamental analysis for Phio Pharmaceuticals Corp yet.
Phio Pharmaceuticals Corp stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Phio Pharmaceuticals Corp
Phio Pharmaceuticals Corp., a clinical stage biopharmaceutical company, engages in the development of immuno-oncology therapeutics in the United States. It develops PH-762, an INTASYL compound designed to reduce the expression of PD-1 in multi-center Phase 1b dose-escalating clinical trials; PH-894, an INTASYL compound that is designed to specifically silence BRD4, a protein that controls gene expression in both T cells and tumor cells in preclinical studies. The company was…
Full company profilePhio Pharmaceuticals Corp financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Phio Pharmaceuticals Corp annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 19.0K | 15.0K | 138K | 21.0K | 4.36K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -5.40M | -5.36M | 138K | 21.0K | -3.72M | -192K | -193K | -6.33M | -3.64M | -4.62M | - |
| Operating Income | -9.02M | -14.1M | -7.36M | -8.99M | -8.79M | -13.5M | -11.5M | -10.8M | -7.39M | -9.22M | -16.9M |
| EBITDA | -8.96M | -14.0M | -7.28M | -8.92M | -8.72M | -13.4M | -11.3M | -10.6M | -7.12M | -8.70M | -16.9M |
| Net Income | -8.99M | -12.5M | -7.36M | -8.84M | -8.79M | -13.2M | -11.3M | -10.8M | -7.15M | -8.70M | -16.4M |
| EPS | -79,593 | -32,768 | -6,216 | -2,074 | -207 | -111 | -90 | -47 | -9.08 | -1.45 | -1.40 |
| Balance Sheet | |||||||||||
| Total Assets | 13.4M | 4.10M | 15.3M | 8.04M | 15.7M | 25.2M | 12.8M | 9.36M | 5.74M | 21.5M | 11.3M |
| Total Liabilities | 2.54M | 2.27M | 1.74M | 2.29M | 2.72M | 3.24M | 1.97M | 1.63M | 1.02M | 1.34M | 2.70M |
| Shareholders' Equity | 10.9M | 1.83M | 13.6M | 5.75M | 13.0M | 21.9M | 10.8M | 7.73M | 4.72M | 20.1M | 8.62M |
| Cash & Short-term Investments | 12.9M | 3.58M | 14.9M | 6.93M | 14.2M | 24.1M | 11.8M | 8.49M | 5.38M | 21.0M | 10.6M |
| Total Debt | - | - | - | 518K | 642K | 295K | 170K | 35.0K | - | - | - |
| Cash Flow | |||||||||||
| Operating Cash Flow | -7.76M | -9.51M | -7.52M | -8.65M | -8.80M | -11.9M | -12.1M | -10.7M | -7.11M | -7.98M | -13.8M |
| Capital Expenditure | 4.00K | 203K | 5.00K | 72.0K | 19.0K | 51.0K | 121K | 5.00K | 1.00K | 12.0K | 0.00 |
| Free Cash Flow | -7.76M | -9.72M | -7.53M | -8.72M | -8.82M | -11.9M | -12.3M | -10.8M | -7.11M | -7.99M | -13.8M |
| Ratios | |||||||||||
| ROE | -82.9% | -679.3% | -54.2% | -153.8% | -67.6% | -60.2% | -104.3% | -140.1% | -151.4% | -43.2% | -190.3% |
| ROA | -67.1% | -303.9% | -48.0% | -110.0% | -55.9% | -52.5% | -88.2% | -115.6% | -124.6% | -40.5% | -144.9% |
| Net Profit Margin | -47,336.8% | -83,013.3% | -5,333.3% | -42,100.0% | -201,604.8% | - | - | - | - | - | - |
| Debt to Equity | - | - | - | 0.09x | 0.05x | 0.01x | 0.02x | 0.00x | - | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Phio Pharmaceuticals Corp dividends
- Dividend yield
- -
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- -
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | - | - | - |
| 2024 | - | - | - |
| 2023 | - | - | - |
| 2022 | - | - | - |
| 2021 | - | - | - |
| 2020 | USD 4.09M | 96 | - |
| 2019 | USD 1.00K | 0.23 | - |
| 2018 | - | - | - |
| 2017 | - | - | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1:9 on Jul 5, 2024.
Who owns Phio Pharmaceuticals Corp
- Insiders 8.25%
- Institutions 10.14%
- Public & others 81.61%
- Shares outstanding 12.0M
- Free float 11.5M
Top funds holding PHIO.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Fidelity Extended Market Index | 51.7K | 0.43% | -51.16% | Sep 2026 |
| Nomura Healthcare Fund Class I | 50.0K | 0.42% | 0.00% | Sep 2026 |
| Fidelity Series Total Market Index | 14.7K | 0.12% | 0.00% | Sep 2026 |
| Fidelity Total Market Index | 13.3K | 0.11% | 0.00% | Sep 2026 |
| Bridgeway Ultra-Small Company | 12.0K | 0.10% | 0.00% | Jun 2026 |
Top institutions holding PHIO.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Jane Street Group LLC | 118K | 0.99% | -1.20% | Jun 2026 |
| Geode Capital Management, LLC | 115K | 0.96% | -22.19% | Jun 2026 |
| Vanguard Capital Management, LLC | 94.3K | 0.79% | +18.04% | Jun 2026 |
| Renaissance Technologies Corp | 57.4K | 0.48% | 0.00% | Sep 2026 |
| Delaware Management Holdings Inc | 50.0K | 0.42% | 0.00% | Jun 2026 |
| Cetera Investment Advisers | 47.5K | 0.40% | +5.56% | Jun 2026 |
| Citadel Advisors Llc | 47.2K | 0.39% | 0.00% | Jun 2026 |
| Vanguard Fiduciary Trust Co | 38.2K | 0.32% | 0.00% | Jun 2026 |
| Northern Trust Corp | 27.8K | 0.23% | +16.88% | Jun 2026 |
| Two Sigma Investments LLC | 21.5K | 0.18% | -33.83% | Jun 2026 |
| XTX Topco Ltd | 18.5K | 0.15% | -25.71% | Jun 2026 |
| HRT FINANCIAL LLC | 13.2K | 0.11% | -62.05% | Jun 2026 |
| Bridgeway Capital Management, LLC | 12.0K | 0.10% | 0.00% | Jun 2026 |
| Citigroup Inc | 11.6K | 0.10% | +1,032.20% | Jun 2026 |
| CapTrust Financial Advisors | 10.0K | 0.08% | 0.00% | Jun 2026 |
| Tower Research Capital LLC | 6.21K | 0.05% | -18.56% | Jun 2026 |
| Morgan Stanley - Brokerage Accounts | 6.00K | 0.05% | 0.00% | Jun 2026 |
| UBS Group AG | 5.39K | 0.05% | -80.04% | Jun 2026 |
| Advisor Group Holdings, Inc. | 2.00K | 0.02% | 0.00% | Jun 2026 |
| Spire Wealth Management | 1.99K | 0.02% | -0.50% | Jun 2026 |
Phio Pharmaceuticals Corp company profile
- Company name
- Phio Pharmaceuticals Corp
- Ticker
- PHIO.US
- Exchange
- USA Stocks
- Listed since
- May 10, 2012
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 6
- Fiscal year end
- December
- Address
- 411 Swedeland Road, King of Prussia, PA, United States, 19406
- Phone
- 610 947 0251
- Website
- phiopharma.com
About Phio Pharmaceuticals Corp
Phio Pharmaceuticals Corp., a clinical stage biopharmaceutical company, engages in the development of immuno-oncology therapeutics in the United States. It develops PH-762, an INTASYL compound designed to reduce the expression of PD-1 in multi-center Phase 1b dose-escalating clinical trials; PH-894, an INTASYL compound that is designed to specifically silence BRD4, a protein that controls gene expression in both T cells and tumor cells in preclinical studies. The company was formerly known as RXi Pharmaceuticals Corporation and changed its name to Phio Pharmaceuticals Corp. in November 2018. Phio Pharmaceuticals Corp. was founded in 2003 and is based in King Of Prussia, Pennsylvania.
Phio Pharmaceuticals Corp management
3- Mr. Robert J. BittermanPresident, CEO & Chairman · born 1951
- Ms. Lisa C. CarsonCFO, Principal Accounting Officer and VP of Finance & Administration · born 1966
- Dr. Jennifer Phillips Pharm.D.Senior Vice President of Regulatory & Corporate Affairs